Clinical Trial: Protective Effect of 5-Alpha Reductase Inhibitors on Atherosclerotic Cardiovascular Disease in Populations With BPH: Evidence From UK Biobank Cohort and Chinese Single Center Database Studies

U.S., Sept. 30 -- ClinicalTrials.gov registry received information related to the study (NCT07196280) titled 'Protective Effect of 5-Alpha Reductase Inhibitors on Atherosclerotic Cardiovascular Disease in Populations With BPH: Evidence From UK Biobank Cohort and Chinese Single Center Database Studies' on Sept. 03.

Brief Summary: To assess the impact of 5-alpha reductase inhibitors (5-ARIs) on the incidence of atherosclerotic cardiovascular disease (ASCVD) in patients with benign prostatic hyperplasia (BPH).

Study Start Date: Jan. 01, 2012

Study Type: OBSERVATIONAL

Condition: Atherosclerotic Cardiovascular Disease (ASCVD) Benign Prostatic Hypertrophy (BPH)

Intervention: DRUG: 5-Alpha Reductase Inhibitors

Building on prior studies, dr...